Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XBD173 for Endothelial Function in Alzheimer's Disease
NCT07191821Phase 2Enrolling by invitation
- Sponsor
- Imperial College London
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emapunil in Alzheimer's disease (AD) (2 arms), sponsored by Imperial College London. Primary endpoint: Change in hippocampal cerebral blood flow (CBF) following a memory task at 4 weeks. Started Aug 2025; status: enrolling by invitation.
02
Drugs
emapunil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07191821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191821.